PipelineReview.com1h
AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer’s Disease and Neuroscience Pipeline
NORTH CHICAGO, IL and BOSTON, MA, USA I8, 2024 I AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which ...
PipelineReview.com1h
Vaxxas Licenses Next-Generation Vaccine for Respiratory Syncytial Virus (RSV) from the United States National Institutes of Health (NIH)
BRISBANE, Australia & CAMBRIDGE, MA, USA I8, 2024 I Vaxxas, a clinical-stage biotechnology company commercializing a novel ...
PipelineReview.com6h
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ORLYNVAH™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades ...
PipelineReview.com6h
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial, which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral ...
PipelineReview.com1d
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
CAMBRIDGE, MA, USA I6, 2024 I Biogen Inc. (Nasdaq: BIIB) – today presented complete results from the Phase 2 IGNAZ study evaluating felzartamab, an ...
PipelineReview.com2d
Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
VANCOUVER, Canada I5, 2024 I Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, ...
PipelineReview.com2d
Traverse Biotech to Present Data on ROR2-Targeted T-Cell Engager at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
NEW YORK, NY, USA I5, 2024 I Traverse Biotech, Inc., a privately held biotechnology company specializing in innovative immunotherapy solutions, today announced that it will present a poster at the ...
PipelineReview.com2d
Jubilant Therapeutics Inc. announces First Patient Dosing in Global Clinical Trials for JBI-802, a CoREST Inhibitor and JBI-778, a PRMT5 Inhibitor
MORRISVILLE, NC, USA I5, 2024 I Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule precision therapeutics to ...
PipelineReview.com2d
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, MD, USA I5, 2024 I LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical ...
PipelineReview.com3d
First Patients Dosed in Phase 1 Clinical Study of ImmunityBio’s CAR-NK Cell Therapy for the Treatment of Relapsed B-Cell Non-Hodgkin Lymphoma
CULVER CITY, CA, USA I October 24, 2024 I Immunotherapy innovator ImmunityBio, Inc. (NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential ...
PipelineReview.com3d
Bayer and Dewpoint Therapeutics sign Licensing Agreement for Heart Disease Program
BERLIN, Germany and BOSTON, MA, USA I4, 2024 I Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart ...
PipelineReview.com3d
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies
SOUTH SAN FRANCISCO, CA, USA I4, 2024 I Lyell Immunopharma, Inc. (Nasdaq: LYEL) announced today that it has entered into a definitive agreement to ...